Skip to main content
. 2015 May 8;3(3):e00141. doi: 10.1002/prp2.141

Figure 7.

Figure 7

Inhibition of lipolysis by FFA2 agonists in primary human adipocytes. (A) Primary human adipocytes were treated with isoproterenol (Iso) or insulin (both at 200 nmol/L) or FFA2 agonists (10–100 μmol/L; only 50 μmol/L treatment is shown) and lipolysis determined as above. Bars represent mean ± SD (n = 4 determinations across two experiment occasions). (B) Primary human adipocytes were pretreated with PTX or vehicle before drug treatment. Bars represent mean ± SD from three experiments with each condition determined in duplicate in each experiment. (C) Primary human adipocytes were pretreated with the hFFA2 antagonist N-CBT (10–50 μmol/L) prior to 4-CMTB treatment. Data show mean ± SD from two experiments, each condition was determined n = 2–4 per experiment. *P < 0.05; **P < 0.01. 4-CMTB, 4-chloro-α-(1-methylethyl)-N-2-thiazolyl-benzeneacetamide; N-CBT, N-(4-Chlorobenzoyl)-l-tryptophan.